216 related articles for article (PubMed ID: 15743746)
1. Altered expression of alpha-methylacyl-coenzyme A racemase in prostatic adenocarcinoma following hormone therapy.
Suzue K; Montag AG; Tretiakova M; Yang XJ; Sahoo S
Am J Clin Pathol; 2005 Apr; 123(4):553-61. PubMed ID: 15743746
[TBL] [Abstract][Full Text] [Related]
2. Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy.
Sung MT; Jiang Z; Montironi R; MacLennan GT; Mazzucchelli R; Cheng L
Hum Pathol; 2007 Feb; 38(2):332-41. PubMed ID: 17134736
[TBL] [Abstract][Full Text] [Related]
3. Variation of alpha-methylacyl-CoA racemase expression in prostate adenocarcinoma cases receiving hormonal therapy.
Tang X; Serizawa A; Tokunaga M; Yasuda M; Matsushita K; Terachi T; Osamura RY
Hum Pathol; 2006 Sep; 37(9):1186-92. PubMed ID: 16938524
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate.
Herawi M; Epstein JI
Am J Surg Pathol; 2007 Jun; 31(6):889-94. PubMed ID: 17527076
[TBL] [Abstract][Full Text] [Related]
5. alpha-methylacyl coenzyme A racemase is immunoreactive in extramammary Paget disease.
Mayes DC; Patterson JW; Ramnani DM; Mills SE
Am J Clin Pathol; 2007 Apr; 127(4):567-71. PubMed ID: 17369131
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of alpha-methylacyl-coenzyme A racemase in colorectal carcinoma bears clinical and pathologic significance.
Lin A; Weiser MR; Klimstra DS; Paty PB; Tang LH; Al-Ahmadie H; Hoo Park S; Guillem JG; Temple L; Wong WD; Gerald WL; Shia J
Hum Pathol; 2007 Jun; 38(6):850-6. PubMed ID: 17442371
[TBL] [Abstract][Full Text] [Related]
7. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.
Luo J; Zha S; Gage WR; Dunn TA; Hicks JL; Bennett CJ; Ewing CM; Platz EA; Ferdinandusse S; Wanders RJ; Trent JM; Isaacs WB; De Marzo AM
Cancer Res; 2002 Apr; 62(8):2220-6. PubMed ID: 11956072
[TBL] [Abstract][Full Text] [Related]
8. Alpha-methylacyl-CoA racemase (P504S) expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone.
Leav I; McNeal JE; Ho SM; Jiang Z
Hum Pathol; 2003 Mar; 34(3):228-33. PubMed ID: 12673556
[TBL] [Abstract][Full Text] [Related]
9. Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl CoA racemase (P504S).
Jiang Z; Woda BA; Wu CL; Yang XJ
Am J Clin Pathol; 2004 Aug; 122(2):275-89. PubMed ID: 15323145
[TBL] [Abstract][Full Text] [Related]
10. Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker.
Jiang Z; Wu CL; Woda BA; Iczkowski KA; Chu PG; Tretiakova MS; Young RH; Weiss LM; Blute RD; Brendler CB; Krausz T; Xu JC; Rock KL; Amin MB; Yang XJ
Histopathology; 2004 Sep; 45(3):218-25. PubMed ID: 15330799
[TBL] [Abstract][Full Text] [Related]
11. S-100A1 is a reliable marker in distinguishing nephrogenic adenoma from prostatic adenocarcinoma.
Cossu-Rocca P; Contini M; Brunelli M; Festa A; Pili F; Gobbo S; Eccher A; Mura A; Massarelli G; Martignoni G
Am J Surg Pathol; 2009 Jul; 33(7):1031-6. PubMed ID: 19384190
[TBL] [Abstract][Full Text] [Related]
12. Alpha-methylacyl-CoA racemase (AMACR) in fine-needle aspiration specimens of prostate lesions.
Kaić G; Tomasović-Loncarić C
Diagn Cytopathol; 2009 Nov; 37(11):803-8. PubMed ID: 19459159
[TBL] [Abstract][Full Text] [Related]
13. Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha methylacyl-CoA racemase (AMACR) in the work-up of prostate cancer.
Kunju LP; Chinnaiyan AM; Shah RB
Histopathology; 2005 Dec; 47(6):587-96. PubMed ID: 16324196
[TBL] [Abstract][Full Text] [Related]
14. [Achievements in morphological diagnosis of prostatic cancer: alpha-methylacyl-coenzyme-A-racemase--a new marker of malignant cell transformation].
Pozharisskiĭ KM; Leenman EE; Arzumanov AA
Arkh Patol; 2005; 67(5):15-9. PubMed ID: 16323473
[TBL] [Abstract][Full Text] [Related]
15. [Detection of P504S (alpha-methylacyl-CoA racemase) in prostatic adenocarcinomas].
Xiao Y; Chen J; Luo YF; Cao JL; Ling Q; Jin F
Zhonghua Yi Xue Za Zhi; 2004 Aug; 84(16):1362-6. PubMed ID: 15387946
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneous expression of alpha-methylacyl-CoA racemase in prostatic cancer correlates with Gleason score.
Murphy AJ; Hughes CA; Lannigan G; Sheils O; O'Leary J; Loftus B
Histopathology; 2007 Jan; 50(2):243-51. PubMed ID: 17222253
[TBL] [Abstract][Full Text] [Related]
17. Alpha-methylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer.
Ananthanarayanan V; Deaton RJ; Yang XJ; Pins MR; Gann PH
Prostate; 2005 Jun; 63(4):341-6. PubMed ID: 15602744
[TBL] [Abstract][Full Text] [Related]
18. Is there a role for fatty acid synthase in the diagnosis of prostatic adenocarcinoma?: A comparison with AMACR.
Wu X; Zayzafoon M; Zhang X; Hameed O
Am J Clin Pathol; 2011 Aug; 136(2):239-46. PubMed ID: 21757596
[TBL] [Abstract][Full Text] [Related]
19. Reliability of the 34βE12, keratin 5/6, p63, bcl-2, and AMACR in the diagnosis of prostate carcinoma.
Boran C; Kandirali E; Yilmaz F; Serin E; Akyol M
Urol Oncol; 2011; 29(6):614-23. PubMed ID: 20189848
[TBL] [Abstract][Full Text] [Related]
20. Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions.
Schostak M; Miller K; Krause H; Schrader M; Kempkensteffen C; Kollermann J
Cancer Detect Prev; 2006; 30(5):449-54. PubMed ID: 17067752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
